サインイン 無料でサインアップします。

Novo Nordisk A/Sの配当性向

Novo Nordisk A/Sの配当性向は何ですか。

Novo Nordisk A/Sの配当性向は27.07%です。

配当性向の定義は何ですか。



配当性向は、株主への配当で支払われる利益の割合です。

The payout ratio is calculated by dividing the dividends paid out by the net earnings for a certain period. It is usually expressed as a percentage. The part of the earnings not paid to investors is left for investment to provide for future earnings growth. Investors seeking high current income and limited capital growth prefer companies with high payout ratio. However investors seeking capital growth may prefer lower payout ratio because capital gains are taxed at a lower rate. High growth firms in early life generally have low or zero payout ratios. As they mature, they tend to return more of the earnings back to investors.

OTCのセクタHealth Careにおける配当性向の企業と比べるNovo Nordisk A/S

Novo Nordisk A/Sは何をしますか。

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/Sと類似の配当性向